<VariationArchive VariationID="551182" VariationName="NM_172250.3(MMAA):c.450dup (p.Pro151fs)" VariationType="Duplication" Accession="VCV000551182" Version="14" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="6" DateLastUpdated="2024-06-17" DateCreated="2018-08-05" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="543081" VariationID="551182">
      <GeneList>
        <Gene Symbol="MMAA" FullName="metabolism of cobalamin associated A" GeneID="166785" HGNC_ID="HGNC:18871" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4q31.21</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="145619385" stop="145660033" display_start="145619385" display_stop="145660033" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="146540539" stop="146581186" display_start="146540539" display_stop="146581186" Strand="+" />
          </Location>
          <OMIM>607481</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_172250.3(MMAA):c.450dup (p.Pro151fs)</Name>
      <CanonicalSPDI>NC_000004.12:145642370:GGG:GGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>4q31.21</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="145642370" stop="145642371" display_start="145642370" display_stop="145642371" variantLength="1" positionVCF="145642370" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="146563522" stop="146563523" display_start="146563522" display_stop="146563523" variantLength="1" positionVCF="146563522" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
      </Location>
      <ProteinChange>P151fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.146563525dup" Assembly="GRCh37">
            <Expression>NC_000004.11:g.146563525dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.145642373dup" Assembly="GRCh38">
            <Expression>NC_000004.12:g.145642373dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007536.2" sequenceAccession="NG_007536" sequenceVersion="2" change="g.48332dup">
            <Expression>NG_007536.2:g.48332dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172250.3" sequenceAccession="NM_172250" sequenceVersion="3" change="c.450dup" MANESelect="true">
            <Expression>NM_172250.3:c.450dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_758454.1" sequenceAccession="NP_758454" sequenceVersion="1" change="p.Pro151fs">
            <Expression>NP_758454.1:p.Pro151fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1301" sequenceAccession="LRG_1301">
            <Expression>LRG_1301:g.48332dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1301t1" sequenceAccession="LRG_1301t1">
            <Expression>LRG_1301t1:c.450dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1301p1" sequenceAccession="LRG_1301p1" change="p.Pro151fs">
            <Expression>LRG_1301p1:p.Pro151fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172250.2" sequenceAccession="NM_172250" sequenceVersion="2" change="c.450dupG">
            <Expression>NM_172250.2:c.450dupG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="754973022" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_172250.3(MMAA):c.450dup (p.Pro151fs) AND Methylmalonic aciduria, cblA type" Accession="RCV000666170" Version="10">
        <ClassifiedConditionList TraitSetID="807">
          <ClassifiedCondition DB="MedGen" ID="C1855109">Methylmalonic aciduria, cblA type</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-03-23" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_172250.3(MMAA):c.450dup (p.Pro151fs) AND Methylmalonic acidemia" Accession="RCV001193916" Version="1">
        <ClassifiedConditionList TraitSetID="9017">
          <ClassifiedCondition DB="MedGen" ID="C0268583">Methylmalonic acidemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-02-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_172250.3(MMAA):c.450dup (p.Pro151fs) AND not provided" Accession="RCV002245082" Version="2">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-03-23" NumberOfSubmissions="6" NumberOfSubmitters="6" DateCreated="2018-08-05" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15523652</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15781192</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20549364</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21048060</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22614770</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28497574</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9017" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6374" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Methylmalonic acidemia</ElementValue>
                <XRef ID="Methylmalonic+acidemia/4713" DB="Genetic Alliance" />
                <XRef ID="HP:0002912" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0002012" DB="MONDO" />
                <XRef ID="42393006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Isolated Methylmalonic Acidemia</ElementValue>
                <XRef ID="C537358" DB="MeSH" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MMA</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7033" />
                <XRef ID="7033" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mutâ€“ enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mutâ€“ enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <XRef ID="C0268583" DB="MedGen" />
              <XRef ID="C537358" DB="MeSH" />
              <XRef ID="MONDO:0002012" DB="MONDO" />
              <XRef Type="primary" ID="HP:0002912" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0003123" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0008295" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="807" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2777" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Methylmalonic aciduria, vitamin B12-responsive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methylmalonic aciduria, vitamin b12-responsive, due to defect in synthesis of adenosylcobalamin, cbla complementation type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MMA cbl A type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methylmalonic acidemia cblA type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Vitamin B12-responsive methylmalonic acidemia type cblA</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Methylmalonic aciduria, cblA type</ElementValue>
                <XRef ID="MONDO:0009613" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">For this GeneReview, the term "isolated methylmalonic acidemia" refers to a group of inborn errors of metabolism associated with elevated methylmalonic acid (MMA) concentration in the blood and urine that result from the failure to isomerize (convert) methylmalonyl-coenzyme A (CoA) into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix, without hyperhomocysteinemia or homocystinuria, hypomethioninemia, or variations in other metabolites, such as malonic acid. Isolated MMA is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mutâ€“ enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, 5-deoxy-adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Prior to the advent of newborn screening, common phenotypes included: Infantile/non-B12-responsive form (mut0 enzymatic subtype, cblB), the most common phenotype, associated with infantile-onset lethargy, tachypnea, hypothermia, vomiting, and dehydration on initiation of protein-containing feeds. Without appropriate treatment, the infantile/non-B12-responsive phenotype could rapidly progress to coma due to hyperammonemic encephalopathy. Partially deficient or B12-responsive phenotypes (mutâ€“ enzymatic subtype, cblA, cblB [rare], cblD-MMA), in which symptoms occur in the first few months or years of life and are characterized by feeding problems, failure to thrive, hypotonia, and developmental delay marked by episodes of metabolic decompensation. Methylmalonyl-CoA epimerase deficiency, in which findings range from complete absence of symptoms to severe metabolic acidosis. Affected individuals can also develop ataxia, dysarthria, hypotonia, mild spastic paraparesis, and seizures. In those individuals diagnosed by newborn screening and treated from an early age, there appears to be decreased early mortality, less severe symptoms at diagnosis, favorable short-term neurodevelopmental outcome, and lower incidence of movement disorders and irreversible cerebral damage. However, secondary complications may still occur and can include intellectual disability, tubulointerstitial nephritis with progressive impairment of renal function, "metabolic stroke" (bilateral lacunar infarction of the basal ganglia during acute metabolic decompensation), pancreatitis, growth failure, functional immune impairment, bone marrow failure, optic nerve atrophy, arrhythmias and/or cardiomyopathy (dilated or hypertrophic), liver steatosis/fibrosis/cancer, and renal cancer.</Attribute>
                <XRef ID="NBK1231" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5500" />
                <XRef ID="5500" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301409</ID>
                <ID Source="BookShelf">NBK1231</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Elevated%20C3%20Acylcarnitine%20PA%20and%20MA.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Elevated C3 Acylcarnitine, Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C3-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Propionic and Methylmalonic Acidemia: C3 Elevated, 2022</CitationText>
              </Citation>
              <XRef ID="28" DB="Orphanet" />
              <XRef ID="79310" DB="Orphanet" />
              <XRef ID="C1855109" DB="MedGen" />
              <XRef ID="MONDO:0009613" DB="MONDO" />
              <XRef Type="MIM" ID="251100" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1540721" SubmissionDate="2018-07-10" DateLastUpdated="2018-08-05" DateCreated="2018-08-05">
        <ClinVarSubmissionID localKey="26244|OMIM:251100" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000790417" DateUpdated="2018-08-05" DateCreated="2018-08-05" Type="SCV" Version="1" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal Recessive and X-Linked Classification Criteria (2018)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/sbjulxjt/counsyl_autosomal_recessive_and_x-linked_classification_criteria_2018_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="4" alternateAllele="TG" referenceAllele="T" start="146563522" stop="146563522" variantLength="1" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.2:c.450dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251100" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4282047</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2671439" SubmissionDate="2020-03-06" DateLastUpdated="2020-06-22" DateCreated="2020-06-22">
        <ClinVarSubmissionID localKey="NM_172250.2:c.450dup|MedGen:C0268583" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001363090" DateUpdated="2020-06-22" DateCreated="2020-06-22" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-02-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21048060</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15781192</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22614770</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28497574</ID>
          </Citation>
          <Comment>Variant summary: The variant, MMAA c.450dupG (p.Pro151AlafsX19) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (eg. c.593_596delCTGA(p.Thr198fsX6)). The variant allele was found at a frequency of 1.2e-05 in 246322 control chromosomes and has been reported in the literature in multiple individuals affected with Methylmalonic Acidemia (Lerner-Ellis_2004, Hauser_2011, Martinez_2005, OShea_2012, and Plessl_2017). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in &lt;10% of normal activity (Lerner-Ellis_2004). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.2:c.450dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Methylmalonic acidemia</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0268583" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6913290</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4068254" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_172250.3:c.450dup|Methylmalonic aciduria cblA type" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002084823" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-11-25">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.3:c.450dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Methylmalonic aciduria cblA type</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2707506" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="4851385|MedGen:C1855109" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001372795" DateUpdated="2024-02-14" DateCreated="2020-07-16" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15781192</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15523652</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20549364</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Pro151Alafs*19) in the MMAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MMAA are known to be pathogenic (PMID: 15523652, 15781192). This variant is present in population databases (rs754973022, gnomAD 0.003%). This premature translational stop signal has been observed in individuals with methylmalonic aciduria cobalamin A type (PMID: 15523652, 20549364). ClinVar contains an entry for this variant (Variation ID: 551182). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.146563522_146563523insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855109" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4924909" SubmissionDate="2022-05-16" DateLastUpdated="2023-03-04" DateCreated="2022-05-21">
        <ClinVarSubmissionID localKey="GDXSV:227290" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002513098" DateUpdated="2023-03-04" DateCreated="2022-05-21" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" OrgAbbreviation="GDX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Not observed at significant frequency in large population cohorts (gnomAD); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 21048060, 22614770, 28497574, 15523652, 20549364)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MMAA" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:39400</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.2:c.450dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_106_20220511054204</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7846091" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_172250.3:c.450dup|OMIM:251100" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004193082" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_172250.3:c.450dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="251100" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4068254" TraitType="Disease" MappingType="Name" MappingValue="Methylmalonic aciduria cblA type" MappingRef="Preferred">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2707506" TraitType="Disease" MappingType="XRef" MappingValue="C1855109" MappingRef="MedGen">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2671439" TraitType="Disease" MappingType="Name" MappingValue="Methylmalonic acidemia" MappingRef="Preferred">
        <MedGen CUI="C0268583" Name="Methylmalonic acidemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4924909" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1540721" TraitType="Disease" MappingType="XRef" MappingValue="251100" MappingRef="OMIM">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7846091" TraitType="Disease" MappingType="XRef" MappingValue="251100" MappingRef="OMIM">
        <MedGen CUI="C1855109" Name="Methylmalonic aciduria, cblA type" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

